A Phase 3, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK0826 and Meropenem in Patients With Complicated UTI.
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Ertapenem (Primary) ; Meropenem
- Indications Urinary tract infections
- Focus Therapeutic Use
- Sponsors Merck & Co
- 28 Apr 2012 Additional locations added as reported by European Clinical Trials Database record.
- 28 Apr 2012 Planned number of patients changed from 410 to 680 as reported by European Clinical Trials Database record.
- 12 Feb 2010 Actual end date changed from May 2009 to Jun 2009 as reported by ClinicalTrials.gov.